5097-82-5Relevant articles and documents
Metal-assisted reactions. Part XXX.* control of rates of heterogeneously catalyzed transfer hydrogenolysis through changes in solvent composition
Alves, Jose A.C.,Brigas, Amadeu F.,Johnstone, Robert A.W.
, p. 423 - 428 (2003)
Adsorption isotherms in the liquid phase can be used to determine the relative strengths of adsorption of reactants and solvent at a catalyst surface. Such isotherms can then be used to indicate which type of solvent would be most suitable for a heterogeneously catalyzed reaction in the liquid-phase. Solubility in any chosen solvent is also important. As examples, rates of heterogeneously catalyzed liquid-phase transfer hydrogenolyzes of aryl tetrazolyl ethers (1) have been shown to be highly dependent on both the nature of the solvent and on the solution concentrations of the reactants. The rate of reaction can be varied from zero to a maximum and then back to zero simply by adjusting the solubility of the redundant through changes in the proportion of water in a mixed-solvent system.
Tetrazole ethers from lignin model phenols: Synthesis, crystal structures, and photostability
Lu,Hu,Osmond,Patrick,James
, p. 1201 - 1206 (2001)
The phenolic OH moiety in lignin is one of the key functional groups responsible for the photo-induced yellowing of mechanical wood pulps and papers. To evaluate new protective groups for the stabilization of lignin phenols, the model compounds, 2-methoxy-4-propylphenol (1) and 4-hydroxy-3-methoxyacetophenone (2) were reacted with 5-chloro-1-phenyl-1H-tetrazole to give the corresponding tetrazole ethers 1′ and 2′, respectively, that were then studied for their photostability. The synthesis of these ethers was more efficient than that of alkyl ethers because of less hydrolysis of the alkylating agent under the reaction conditions. Compounds 1′ and 2′ were fully characterized, including X-ray crystal structure analyses. Crystals of 1′ and 2′ were monoclinic of space groups P21/c and P21/a, respectively. For 1′: a = 9.8679(6), b = 16.708(1), c = 10.2841(6) A, β = 109.732(5)°, Z = 4. For 2′: a = 7.7212(2), b = 27.350(5), c = 14.569(3) A, β = 101.30(2)°, Z = 8. The structures were solved by direct methods and refined by full-matrix least-squares procedures to R = 0.039 (Rw = 0.046) for 2029 reflections with I ≥ 3σ(I) (for 1′), and to R = 0.055 (Rw = 0.073) for 3634 reflections with I ≥ 3σ(I) (for 2′). Compound 2′ was much more photostable than the precursor phenol on exposure to strong fluorescent light, while 1′ was only slightly more stable than the precursor phenol.
Method for synthesizing 1-phenyl-5-hydroxytetrazole in continuous-flow tubular reactor
-
Paragraph 0016-0024, (2021/11/26)
The invention relates to the technical field of medicine synthesis, in particular to a method for synthesizing 1-phenyl-5-hydroxytetrazole in a continuous-flow tubular reactor. Specifically, in the continuous-flow tubular reactor, phenyl isocyanate and azidotrimethylsilane are used as raw materials to synthesize a target product. According to the method, the continuous-flow tubular reactor is adopted, so reaction time is greatly shortened, a contact area of reactants is large, an automation degree is high, control is convenient, an aftertreatment operation process is simplified, efficiency is high, time and labor cost are saved, yield reaches 95% or above, target product selectivity can reach 100%, emission of organic waste liquid is reduced, and environmental protection is facilitated.
TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
-
Paragraph 495-497, (2020/07/31)
The present disclosure relates to compounds of formula (AI), (I), (AII), and (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (AI), (I), (AII), and (II), and use thereof, wherein R2, R3, R4, R5, R6, R7, R10, R11a, R11b, R12, R16, R19a, R19b, and R20 are described herein. Such compounds are envisioned useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, movement disorders, convulsive disorders, schizophrenin spectrum disorders, disorders of memory and/or cognition, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, or tinnitus etc.
Synthesis and antileishmanial activity of 1,2,4,5-tetraoxanes against leishmania donovani
Cabral, Lília I.L.,Pomel, Sébastien,Cojean, Sandrine,Amado, Patrícia S.M.,Loiseau, Philippe M.,Cristiano, Maria L.S.
supporting information, (2020/02/11)
A chemically diverse range of novel tetraoxanes was synthesized and evaluated in vitro against intramacrophage amastigote forms of Leishmania donovani. All 15 tested tetraoxanes displayed activity, with IC50 values ranging from 2 to 45 μm. The most active tetraoxane, compound LC140, exhibited an IC50 value of 2.52 ± 0.65 μm on L. donovani intramacrophage amastigotes, with a selectivity index of 13.5. This compound reduced the liver parasite burden of L. donovani-infected mice by 37% after an intraperitoneal treatment at 10 mg/kg/day for five consecutive days, whereas miltefosine, an antileishmanial drug in use, reduced it by 66%. These results provide a relevant basis for the development of further tetraoxanes as effective, safe, and cheap drugs against leishmaniasis.
NEW ENDOPEROXIDE COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES THEREOF FOR CONTROL OF PERKINSIOSIS IN BIVALVES
-
Page/Page column 22, (2020/12/11)
The present invention relates to new endoperoxide compounds and compositions, and to a process for producing them for prophylaxis and control of perkinsiosis in bivalves. Endoperoxide compounds with biological activity against Perkinsus olseni include 13
PROCESS FOR THE PRODUCTION OF TETRAZOLINONES
-
Page/Page column 11; 12, (2019/11/12)
The invention relates to a process for the preparation of a tetrazolinone compound, comprising a step of reacting an isocyanate compound with an azide salt in a solvent and in the presence of a silicon derivative as a catalyst.
FUMARATE ANALOGS AND USES THEREOF IN THE TREATMENT OF AN AUTOIMMUNE DISEASE OR AN INFLAMMATORY DISEASE
-
Paragraph 00430; 00431, (2016/04/19)
Aspects of the present disclosure include compounds of formula (A) that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that in
Tetrazolones as a Carboxylic Acid Bioisosteres
-
Paragraph 0245; 0246; 0247; 0248; 0249; 0250, (2016/08/17)
The present disclosure provides compounds that include a tetrazolone derivative of a carboxyl group of an active agent. This disclosure also relates to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.
A one-pot synthesis of tetrazolones from acid chlorides: Understanding functional group compatibility, and application to the late-stage functionalization of marketed drugs
Duncton, Matthew A. J.,Singh, Rajinder
supporting information, p. 9338 - 9342 (2016/10/13)
A one-pot and scalable synthesis of tetrazolones (tetrazol-5-ones) from acid chlorides using azidotrimethylsilane is presented. The reaction tolerates many functional groups and can furnish aryl-, heteroaryl-, alkenyl-, or alkyl-substituted tetrazolone products in moderate to excellent yield (14-94%). No reduction in yield was observed when the reaction was undertaken on a larger-scale (20-36 g). The method could be used for the late-stage functionalization of pharmaceuticals, to provide tetrazolone congeners of the marketed drugs aspirin, indomethacin, probenecid, telmisartan, bexarotene, niacin (vitamin B3), and the active metabolite of the recently-launched immuno-modulatory agent, BG-12 (Tecfidera). The ability of a tetrazolone group to serve as a bioisostere of a carboxylic acid, and to improve drug pharmacokinetic profiles is also highlighted.
